Mitiglinide

Summary

Mitiglinide (CHEMBL471498) is a phase-3 clinical-stage small molecule (ATC A10BX08); indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A10BX08
• Indications: 2 conditions
• Clinical trials: 10
• Chemistry: 315.4 Da · C19H25NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL471498
Name	Mitiglinide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	121891
ATC	A10BX08
Molecular formula	C19H25NO3
Molecular weight	315.4
InChIKey	WPGGHFDDFPHPOB-BBWFWOEESA-N

SMILES: C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O

IUPAC name: (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid

Also known as: Mitiglinida, Mitiglinide, mitiglinide, MITIGLINIDE, Mitiglinide Calcium

Parent form; salt/anhydrous children: CHEMBL1603301

Patent coverage: 1,683 distinct patent families (6,765 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	3	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00663884	PHASE4	COMPLETED	Glufast On Insulin Glargine Trial in Type 2 DM
NCT02143765	PHASE4	COMPLETED	Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
NCT02503943	PHASE4	UNKNOWN	Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
NCT04349696	PHASE4	COMPLETED	Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)
NCT00461617	PHASE3	COMPLETED	Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
NCT00519142	PHASE3	COMPLETED	Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
NCT01037842	PHASE3	COMPLETED	Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus
NCT07444424	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
NCT01422590	PHASE1	COMPLETED	Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin
NCT01443221	PHASE1	COMPLETED	Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).